Vimkunya is the first FDA-approved vaccine for chikungunya in patients over 12 years of age.
FDA Approves Bavarian Nordic’s Chikungunya Vaccine Vimkunya
Vimkunya is the first FDA-approved vaccine for chikungunya in patients over 12 years of age.
You may also like
How Abpro Plans to Leverage the Public Markets
FDA Approves Samsung Bioepis Biosimilars Ospomyv and...
Global Launch Strategies in the Current Political...
Epitopea Strikes Research Collaboration with Merck...
Former Health Agency Heads React to Federal Layoffs at...
Applyo Jena Closes Successful Series A Funding Round
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.